Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Williams Companies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Williams Companies Inc trades at $75.86 (market cap $91.75B). The key difference: Williams Companies Inc is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Williams Companies Inc pays a 2.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMB | |
|---|---|---|
Market Cap | $39.89B | $91.75B |
Sector | Health | Energy |
52-Week High | $491.22 | $79.40 |
52-Week Low | $278.09 | $56.51 |
Enterprise Value | $38.15B | $121.14B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Williams Companies (WMB) trades at $75.02, down 0.57% on the day, with strong analyst consensus (79% buy ratings) and a $85.58 price target suggesting 14% upside. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust profitability (23.4% net margin) and positive cash flow trends. Recent news highlights WMB's potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure.
WMB presents a compelling investment case with stable fee-based revenue, dividend growth potential, and strategic expansion plans. Key risks include execution of large acquisitions, commodity price volatility exposure, and high debt levels. The current valuation at 32.9x P/E appears elevated but justified by strong earnings growth and sector-leading margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
